FDA Issues Warning of Guillain-Barré Syndrome Risk for 2 RSV Vaccines

The respiratory syncytial virus (RSV) vaccines marketed as Abrysvo by Pfizer and Arexvy by GSK will now require a warning about the risk of Guillain-Barré syndrome (GBS), the US Food and Drug Administration (FDA) announced recently.

Authors

Publication Details

Journal
JAMA
Published
2025-02-21
DOI
https://doi.org/10.1001/jama.2025.0545
Citations
2
Primary Topic
Peripheral Neuropathies and Disorders
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FDA Issues Warning of Guillain-Barré Syndrome Risk for 2 RSV Vaccines

Samantha Anderer
2 citations
JAMA
Peripheral Neuropathies and Disorders
2.78
article

FDA Issues Warning of Guillain-Barré Syndrome Risk for 2 RSV Vaccines

Samantha Anderer
article en
2 citations

Abstract

The respiratory syncytial virus (RSV) vaccines marketed as Abrysvo by Pfizer and Arexvy by GSK will now require a warning about the risk of Guillain-Barré syndrome (GBS), the US Food and Drug Administration (FDA) announced recently.

JAMAVol. 333(12)
Openalex Percentile: Top 12%
Peripheral Neuropathies and Disorders
2.78
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FDA Issues Warning of Guillain-Barré Syndrome Risk for 2 RSV Vaccines — Samantha Anderer · JAMA (2025) | TGRS Research Map | TGRS